Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MLTX

MoonLake Immunotherapeut... (MLTX)

MoonLake Immunotherapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MLTX
DateTimeSourceHeadlineSymbolCompany
12/18/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
11/13/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNASDAQ:MLTXMoonLake Immunotherapeutics
11/07/20246:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
11/07/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
11/07/20246:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
10/08/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
09/11/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
09/09/20246:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11NASDAQ:MLTXMoonLake Immunotherapeutics
08/07/20247:04AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
08/07/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
08/07/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11NASDAQ:MLTXMoonLake Immunotherapeutics
06/10/20243:40PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
06/10/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisNASDAQ:MLTXMoonLake Immunotherapeutics
06/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/07/20243:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/07/20243:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/06/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
05/16/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaNASDAQ:MLTXMoonLake Immunotherapeutics
05/07/20247:02AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
05/07/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
05/07/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
05/07/20246:57AMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MLTXMoonLake Immunotherapeutics
04/10/20246:00AMBusiness WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsNASDAQ:MLTXMoonLake Immunotherapeutics
04/10/20246:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions NASDAQ:MLTXMoonLake Immunotherapeutics
03/11/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
03/10/202411:00AMGlobeNewswire Inc.MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayNASDAQ:MLTXMoonLake Immunotherapeutics
03/04/20247:00AMGlobeNewswire Inc.MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024NASDAQ:MLTXMoonLake Immunotherapeutics
02/29/20246:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
02/29/20246:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
 Showing the most relevant articles for your search:NASDAQ:MLTX